Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB01323"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label |
"St. John's Wort"
|
| rdf:type | |
| ns1:description |
"
nutraceutical
# Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12153829
# Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16423519
# : Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11939866
Trevor Percival Castor, Theodore Abraham Tyler, Richard Joseph Student, "Methods for making Hypericum fractions and St. John's Wort products." U.S. Patent US6291241, issued December, 1998.
Guna Inc.
http://www.gunainc.com
Pekana Naturheilmittel GmbH
http://www.pekana.com
Weleda Inc.
http://www.weleda.com
DB00404
Alprazolam
St. John's Wort may decrease the effect of the benzodiazepine, alprazolam.
DB01223
Aminophylline
St. John's Wort decreases the effect of theophylline
DB00701
Amprenavir
St. John's Wort decreases the effect of indinavir
DB01072
Atazanavir
St. John's Wort decreases the levels/effects of atazanavir
DB06626
Axitinib
Avoid combination due to the likely decreased levels of axitinib.
DB08873
Boceprevir
Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB06772
Cabazitaxel
Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB08875
Cabozantinib
Avoid combination. May decrease concentration of cabozantinib. Also avoid all other strong CYP3A4 inducers.
DB00215
Citalopram
St. John's Wort increases the effect and toxicity of the SSRI, citalopram.
DB01068
Clonazepam
St. John's Wort may decrease the effect of the benzodiazepine, clonazepam.
DB00091
Cyclosporine
St. John's Wort decreases the effect of cyclosporine
DB00705
Delavirdine
St. John's Wort decreases the antiretroviral effect
DB06700
Desvenlafaxine
Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00829
Diazepam
St. John's Wort may decrease the effect of the benzodiazepine, diazepam.
DB00390
Digoxin
St. John's Wort decreases the effect of digoxin
DB00625
Efavirenz
St. John's Wort decreases the antiretroviral effect
DB00530
Erlotinib
Decreased levels/effect of erlotinib
DB01175
Escitalopram
St. John's Wort increases the effect and toxicity of the SSRI, escitalopram.
DB08866
Estradiol valerate/Dienogest
Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00977
Ethinyl Estradiol
St. John's Wort could reduce the contraceptive effect
DB06414
Etravirine
Etravirine may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00472
Fluoxetine
St. John's Wort increases the effect and toxicity of the SSRI, fluoxetine.
DB00176
Fluvoxamine
St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine.
DB01319
Fosamprenavir
St. John's Wort decreases the effect of indinavir
DB00317
Gefitinib
The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00619
Imatinib
St. John's Wort decreases levels of imatinib
DB00224
Indinavir
St. John's Wort decreases the effect of indinavir
DB08820
Ivacaftor
Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB00333
Methadone
St. John's Wort decreases levels/effect of methadone
DB00683
Midazolam
St. John's Wort may decrease the effect of the benzodiazepine, midazolam.
DB01149
Nefazodone
St. John's Wort increases the effect and toxicity of the SSRI, nefazodone.
DB00220
Nelfinavir
St. John's Wort decreases the effect of indinavir
DB00238
Nevirapine
St. John's Wort decreases nevirapine effect
DB01115
Nifedipine
St. John's Wort decreases the effect of nifedipine
DB00717
Norethindrone
St. John's Wort could reduce the contraceptive effect
DB00338
Omeprazole
St. John's Wort decreases the levels/effects of omeprazole
DB01303
Oxtriphylline
St. John's Wort decreases the effect of theophylline
DB01229
Paclitaxel
Avoid combination due to potential decrease in serum concentration of paclitaxel.
DB00715
Paroxetine
St. John's Wort increases the effect and toxicity of the SSRI, paroxetine.
DB08883
Perampanel
Avoid combination due to the potential decrease in perampanel concentration.
DB01367
Rasagiline
Increased risk of toxicity with this association
DB08896
Regorafenib
Strong CYP3A4 inducers may decrease levels of regorafenib.
DB01656
Roflumilast
Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00864
Tacrolimus
St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered.
DB06287
Temsirolimus
St. John's Wort may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00277
Theophylline
St. John's Wort decreases the effect of theophylline
DB00932
Tipranavir
St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided.
DB06212
Tolvaptan
St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB00193
Tramadol
Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00752
Tranylcypromine
Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00656
Trazodone
Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00897
Triazolam
St. John's Wort may decrease the effect of the benzodiazepine, triazolam.
DB00726
Trimipramine
St. John's Wort may decrease serum concentrations of Trimipramine. Possible increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if St. John's Wort is initiated, discontinued or dose changed.
DB08867
Ulipristal
Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB05294
Vandetanib
Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00285
Venlafaxine
Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00582
Voriconazole
St. John's Wort may decrease the serum concentration of voriconazole by increasing its elimination. Concomitant therapy is contraindicated.
DB00682
Warfarin
St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed.
DB00315
Zolmitriptan
Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Drugs Product Database (DPD)
2119897
PharmGKB
PA164924486
Wikipedia
St_John%27s_wort
Drugs.com
http://www.drugs.com/cdi/st-john-s-wort.html
BE0001032
Multidrug resistance protein 1
Human
inducer
# Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11180019
unknown
Multidrug resistance protein 1
Defense mechanisms and drug export
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells
ABCB1
7q21.1
Membrane; multi-pass membrane protein
52-72
120-140
189-209
216-236
297-317
326-346
711-731
757-777
833-853
854-874
937-957
974-994
9.44
141464.0
Human
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
UniProtKB
P08183
UniProt Accession
MDR1_HUMAN
ATP-binding cassette sub-family B member 1
CD243 antigen
EC 3.6.3.44
P-glycoprotein 1
>Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGAGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ
>3843 bp
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCT
AAGATTAATGAAGTTATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGCCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTGCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATCGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA
PF00005
ABC_tran
PF00664
ABC_membrane
component
cell
component
intrinsic to membrane
component
integral to membrane
component
membrane
function
catalytic activity
function
hydrolase activity, acting on acid anhydrides
function
hydrolase activity
function
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides
function
nucleotide binding
function
pyrophosphatase activity
function
purine nucleotide binding
function
nucleoside-triphosphatase activity
function
adenyl nucleotide binding
function
ATPase activity
function
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
function
ATPase activity, coupled to transmembrane movement of substances
function
binding
function
ATP binding
process
transport
process
physiological process
process
cellular physiological process
"
|
| ns1:interactsWith | |
| owl:sameAs |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/drugbank_small.nt
The resource appears as object in 117 triples